MARCH 21: India’s first wave of affordable, patent‑free obesity injections is set to hit the market, with monthly costs for semaglutide‑based weight‑loss shots expected to fall from ₹9,000–₹28,000 to about ₹3,000–₹4,000. The move follows the expiry of Danish drugmaker Novo Nordisk’s patent on semaglutide, the key ingredient in blockbuster brands like Ozempic and Wegovy, opening the door for Indian generics from companies such as Eris Lifesciences and others.
But the bigger change is what comes along with the injection. Doctors and clinics are shifting from a “quick‑fix” mindset to a structured weight‑loss ecosystem, in which GLP‑1 shots are bundled with diet plans, dermatology consultations, regular follow‑ups, and specialised obesity‑care pathways. This “broad‑base” model is being described as a turning point in how India treats obesity and type‑2 diabetes, bringing advanced metabolic care into the reach of middle‑ and upper‑middle‑income patients.
Endocrinologists warn that cheaper access must be matched with strict monitoring, because of potential side effects, incorrect self‑use, and the risk of treating fat‑loss jabs as cosmetic “lifestyle” products rather than medical interventions. Regulatory bodies and medical associations are already pushing for clearer prescribing guidelines and tighter oversight to prevent misuse as the country enters a new era of mass‑market obesity treatment.
